News

Filter

Current filters:

EisaiOncology

1 to 9 of 76 results

Helsinn grants Stendhal rights to NEPA in several Latin America countries

02-02-2015

Family-run Swiss oncology specialist Helsinn has granted exclusive rights to Mexico-based Especificos…

AkynzeoEisaiHelsinnLicensingNEPAnetupitantOncologypalonosetronPharmaceuticalSouth AmericaStendhal

German Federal Joint Committee confirms 'considerable' benefit of Eisai's Halaven in breast cancer

German Federal Joint Committee confirms 'considerable' benefit of Eisai's Halaven in breast cancer

23-01-2015

The German Federal Joint Committee has confirmed the ‘considerable’ additional benefit of Japanese…

EisaiGermanyHalavenOncologyPharmaceuticalRegulation

Helsinn settles with Sandoz over Aloxi in USA

12-01-2015

Privately-held Swiss cancer specialist Helsinn Group say it has entered into a settlement agreement with…

AloxiEisaiGenericsHelsinn GroupLegalNovartisOncologyPatentsSandozUSA

Drugmakers “outraged” at England's Cancer Drugs Fund decision to remove drugs from coverage

Drugmakers “outraged” at England's Cancer Drugs Fund decision to remove drugs from coverage

08-01-2015

England’s Cancer Drugs Fund is overspent and 42 drugs are being reassessed as price caps are brought…

AvastinEisaiHalavenHealthcareJevtanaKadcylaOncologyPharmaceuticalPricingRocheSanofiUKZaltrap

Eisai's Halaven now available in Russia for advanced breast cancer

Eisai's Halaven now available in Russia for advanced breast cancer

18-12-2014

Halaven (eribulin) manufactured by Japanese drug major Eisai is now available in Russia.

EisaiHalavenOncologyPharmaceuticalRegulationRussia

IQWIG confirms an additional benefit of Eisai's Halaven

IQWIG confirms an additional benefit of Eisai's Halaven

04-11-2014

Following a benefit:cost re-assessment, the German Institute for Quality and Efficiency in Health Care…

EisaiGermanyHalavenOncologyPharmaceuticalPricingRegulation

FDA grants priority reviews for Eisai's for rufinamide and lenvatinib

FDA grants priority reviews for Eisai's for rufinamide and lenvatinib

15-10-2014

There was good news for Japanese drugmaker Eisai yesterday, as the US Food and Drug Administration granted…

BanzelEisailenvatinibNeurologicalOncologyPharmaceuticalRegulationRufinamide TabletsUSA

FDA approves Eisai’s Akynzeo for CINV

13-10-2014

The US Food and Drug Administration has approved Japanese pharma major Eisai’s Akynzeo (netupitant…

AkynzeoEisaiHelsinnnetupitantOncologypalonosetronPharmaceuticalRegulationUSA

1 to 9 of 76 results

COMPANY SPOTLIGHT

Menarini

Back to top